[ad_1]
The World Health Organization (WHO) has announced that more data is needed to evaluate the efficacy of a new vaccine against coronavirus infection (Corona 19), which was jointly developed by the pharmaceutical multinational AstraZeneca and the University of Oxford in the United Kingdom.
Sumya Swaminatan, WHO chief scientist, stressed that the clinical scale is small enough to draw a firm conclusion about the vaccine’s efficacy at a video news conference on 27 (local time), the Associated Press said.
Earlier, the University of Oxford AstraZeneca had announced on the 23rd that the average immune effect was 70% as a result of the initial data analysis of a phase 3 clinical trial of a vaccine in development.
The prophylactic effect was 90% in the clinical group in which half of the vaccine was given first and the full dose was given one month later, and 62% in the group that received the full dose intact.
At that time, the number of clinical participants was 2,741 in the first group and 8,895 in the second group.
AstraZeneca-Oxford University said it plans to give the full dose to all clinical subjects, but explained that some were given only half the dose due to the researchers’ dose measurement error.
However, many experts pointed out the difference in efficacy by dosage and questioned the reliability of the vaccine itself, which was controversial.
In this regard, Swaminatan’s chief scientist said: “It is very difficult to compare the two groups.”
Earlier, Pascal Sorio AstraZeneca, CEO of AstraZeneca, told Bloomberg News on the 26th that “Since we have found a way that works better, we need to prove it.”
▶ View the latest Corona 19 current status and response
Source link
